Abstract 33P
Background
Breast cancers that test positive for the human epidermal growth factor receptor 2 (HER2+) are known to be highly aggressive and hold poor survival rates. However, advances in therapies targeting HER2 have led to anti-HER2 antibodies like Trastuzumab and tyrosine kinase inhibitors. Trastuzumab-deruxtecan (Tz-Dxd) is an antibody-drug conjugate that has shown remarkable results in both HER2+ and HER2-low BCa. By promoting its internalization and trafficking to lysosomes through HER2 binding, Tz-Dxd has great potential to revolutionize cancer treatment.
Methods
This study aimed to investigate the effects of Tz-Dxd on HER2+ breast cancer cell lines at the nanoscale level using high-resolution light and electron microscopy techniques, biochemistry and flow cytometry analysis.
Results
We found that after 2 hours, Tz-Dxd induced ERBB2 phosphorylation and downstream signaling activation without significant internalization of the receptor. However, the receptor was internalized towards lysosomes at later stages (72 hours), but only in a limited fraction of cells. Nonetheless, Tz-Dxd induced apoptosis in more than 50% of cells after 72 hours of treatment, even in cells where ERBB2/Tz-Dxd was not internalized. This suggests that deruxtecan was efficiently released from Tz in lysosomes reaching by diffusion surrounding cells. In addition to apoptotic cells, we observed a consistent fraction of cells displaying suggestive hallmarks of senescence. In particular, we detected dramatic cell flattening, increased nuclear size, chromatin reorganization, nuclear envelope ruptures and expansion of the lysosomal compartment. Cells also displayed alterations of the mitochondrial network dynamics and induction of autophagy; indicative of an elevated energy demand to sustain autophagy and senescence.
Conclusions
These results suggest that Tz-Dxd has potent anti-tumor activity in vitro but might also induce cellular senescence, which would merit further investigation due to its uncertain role in cancer progression in the long run.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Academic group.
Funding
Has not received any funding.
Disclosure
O. Garrone: Financial Interests, Institutional, Advisory Board: Eisai, MSD, Daiichi Sankyo, Gilead; Financial Interests, Personal, Financially compensated role: Novartis, Pfizer, Lilly. All other authors have declared no conflicts of interest.
Resources from the same session
46P - Effect of coadministration of antioxidant chlorophyllin with docetaxel on invasion and metastasis in triple-negative breast cancer in vivo/in vitro
Presenter: Ayse Burus
Session: Poster session 09
47P - An ozone delivery system by cisplatin prodrug self-assembling micelles combining microwave to sensitizing immune checkpoint inhibitor in triple-negative breast cancer
Presenter: Dan Zheng
Session: Poster session 09
48P - Non-steroid anti-inflammatory treatment enhances the efficacy of modulated electro hyperthermia on triple-negative breast cancer and melanoma cancer models in vivo
Presenter: Nino Giunashvili
Session: Poster session 09
49P - Circulating miRNA signatures to predict recurrence in patients with pathological complete response of triple-negative breast cancer
Presenter: Ana Julia de Freitas
Session: Poster session 09
50P - Application and mechanism of tarloxotinib in HER2-positive breast cancer
Presenter: Xinyi Shao
Session: Poster session 09
51P - Nanoengineered sonosensitive platelets for synergistically augmented sonodynamic breast tumour therapy by glutamine deprivation and cascading thrombosis
Presenter: Liqiang Zhou
Session: Poster session 09
53P - Treatment of cancer cells based on circulating tumor cell’s expression profile using off-label drugs
Presenter: Panagiotis Apostolou
Session: Poster session 09
54P - Enhanced oxidative phosphorylation of metastasis-initiating cells facilitates esophageal tumor cell seeding in lymph nodes
Presenter: Shanshan Li
Session: Poster session 09
55P - Transcriptional profiles of engineered T cells stimulated with different receptor structures and co-stimulatory domains
Presenter: Ungue Shin
Session: Poster session 09
56P - SLC34A2-ROS1 L2026M+G2032R confers resistance to ROS1 tyrosine kinase inhibitors in Ba/F3 cells through a reduced ATP binding pocket volume
Presenter: Christa Dijkhuizen
Session: Poster session 09